Brandy Betz is an experienced freelance writer in the industries.
Former writer for The Motley Fool specializing in the finance of healthcare, technology, and retail.
When best-selling cholesterol drug Lipitor fell off the patent cliff in 2011, the question became, "What's next?" A hot new class of treatments called PCSK9 inhibitors want to become the answer. Sanofi (NYSE: SNY ) and Rege...
Your first month is on us.